MA Research Update — September 15, 2026
Updated Thesis
Mastercard operates a global payments network that connects issuers, acquirers, merchants and consumers across more than 200 countries and territories, monetizing payment volumes, cross-border activity and higher-growth value-added services. Business quality is high because its two-sided network, trusted authorization-clearing-settlement infrastructure, brand, security capabilities and broad acceptance create durable barriers; TTM operating and net margins are 59.8% and 46.3%, respectively, while revenue grew 14.1% and earnings grew 18.6% year over year in the most recent quarter. The shares appear undervalued versus the $718 fair-value estimate and $718 consensus target, implying 25.0% upside from $574.42, and screen cheap relative to their five-year valuation history, although the absolute valuation remains demanding at 31.16x trailing earnings, 14.36x sales, 30.8x free cash flow and 23.38x EV/EBITDA.
The investment grade as of this refresh is A- — high business quality. A-tier business, B-tier valuation; 25.0% upside to $718 fair value is attractive, but below the threshold for High conviction and balanced by regulatory, litigation and alternative-rail risks.
Key Metrics at a Glance
- Revenue growth: +14.1% year over year
- Net margin: 46.3%
- Fair value upside: +25.0% to our estimate of $718
Current price: $574.42
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Mastercard Incorporated remains in our covered universe with a high-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full MA research →](/stocks/MA)